Redeye comments on Annexin’s Q3 report and recent events. The company is about to start a clinical phase IIa study in patients with diabetic retinopathy (DR) and retinal vein occlusion (RVO) - two severe eye diseases with significant market opportunities. The study has been slow-started, but the company is taking steps to ramp up recruitment. We adjust our financial assumptions, resulting in a slightly revised valuation.
LÄS MER
